EOS imaging has received approval from the US Food and Drug Administration for its Micro Dose feature for pediatric imaging.
Micro Dose feature has been developed for patients with orthopedic conditions requiring frequent imaging exams for the continuous monitoring of disease progression and treatment.
EOS imaging CEO EOS imaging said: "The reduction of radiation exposure during orthopedic imaging exams remains a foremost concern among radiologists, orthopedic surgeons and patients.
"The Micro Dose solution is a giant step forward and is in full accordance with the ALARA (As Low As Reasonably Achievable) principle."
EOS imaging noted that Micro Dose generates dosage levels equivalent to a week of naturally-occurring background radiation in pediatric patients receiving 2D and 3D follow-up examinations.
The initial results of the Micro Dose were presented at the 2013 French Society of Radiology Annual Meeting (JFR 2013) and during the 2014 Annual Meeting of the Radiological Society of North America (RSNA 2014).